Tweetorial #3: Best Practices with T-cell Therapy
Post-Survey & Application for CME Credit

In order to receive credit for this activity, you must read the front matter, view the activity, achieve a passing of at least 100% on this post-survey, as well as complete the linked evaluation and application for credit form. Certificates of credit will be emailed to participants who have successfully met these requirements.

There is no fee to participate in this activity.

Question Title

* 1. What are your credentials?

Hematologist

Medical Oncologist

Surgical Oncologist, Radiation Oncologist, or Pathologist

Other MD/DO

Fellow/Trainee

Advanced Practice Provider

Nurse

Pharmacist

Other (please specify)

Question Title

* 2. What is your community of practice?

Academic

Community

Industry

Other (please specify)

Question Title

* 3. Based on an Association of Community Cancer Centers @ACCCBuzz survey conducted in 2020, which of the following challenges was most frequently cited as a barrier to treatment with bispecific antibodies?

Transitions of care

Managing remote patients

Insurance coverage

Managing adverse effects

Question Title

* 4. 74-YOM dx w/ IgG MM w/ t(11;14) here discuss tx with a bispecific ab. After explaining tx is continued until disease progression, he asks if he needs to receive tx and monitoring at an academic center. Which of the following is the best response regarding where tx is delivered?

Only academic centers

Only community practice

Only in hospital

Community and/or academic

Question Title

* 5. The director of the cancer center is exploring providing bispecific antibodies or CAR-T for multiple myeloma. Which of the following processes would need to be developed in order to provide both CAR-T and bispecific antibodies?

Leukapheresis

Adverse event counseling

Stem cell mobilization

T-cell re-engineering

EVALUATION FORM

Question Title

* 6. Upon completion of this activity, I am able to:

	Strongly agree	Agree	Disagree	Strongly disagree
TRANSLATE strategies to monitor and minimize the negative impact of treatment-related toxicities for BCMA-directed therapies in RRMM	TRANSLATE strategies to monitor and minimize the negative impact of treatment-related toxicities for BCMA-directed therapies in RRMM Strongly agree	TRANSLATE strategies to monitor and minimize the negative impact of treatment-related toxicities for BCMA-directed therapies in RRMM Agree	TRANSLATE strategies to monitor and minimize the negative impact of treatment-related toxicities for BCMA-directed therapies in RRMM Disagree	TRANSLATE strategies to monitor and minimize the negative impact of treatment-related toxicities for BCMA-directed therapies in RRMM Strongly disagree

Question Title

* 7. Please indicate the extent of your agreement with the following statements:

	Strongly agree	Agree	Disagree	Strongly disagree
The faculty for this activity were effective.	The faculty for this activity were effective. Strongly agree	The faculty for this activity were effective. Agree	The faculty for this activity were effective. Disagree	The faculty for this activity were effective. Strongly disagree
The educational resources provided to me at the educational activity are useful to my practice.	The educational resources provided to me at the educational activity are useful to my practice. Strongly agree	The educational resources provided to me at the educational activity are useful to my practice. Agree	The educational resources provided to me at the educational activity are useful to my practice. Disagree	The educational resources provided to me at the educational activity are useful to my practice. Strongly disagree

Question Title

* 8. Overall, was this activity fair, balanced and free from commercial bias?

Yes

Question Title

* 9. If no, please explain:

Question Title

* 10. Of the patients you will see in the next month, about how many will benefit from the information you learned today?

1 to 5

6 to 10

11 to 20

≥ 21

I am not directly involved in patient care

Question Title

* 11. As a result of what I learned, I intend to make changes in my practice:

Extremely likely

Somewhat likely

Not at all likely

Question Title

* 12. What change(s) will you incorporate into your practice as a result of what you have learned in this activity?

Improved diagnosis/patient assessment

Useful therapies and appropriate uses

Cutting-edge science in this therapeutic area

Best practices of my colleagues and leaders

I do not plan on making changes to my practice at this time

Question Title

* 13. Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):

Lack of knowledge regarding evidence-based strategies

Lack of convincing evidence to warrant change

Lack of time/resources to consider change

Insurance, reimbursement or legal issues

Patient adherence/resistance to change

Question Title

* 14. I certify that I have participated in the continuing education activity entitled, "Not Just Another Monoclonal Antibody: Best Practices for Providing T-cell Therapies" and claim 0.25 AMA PRA Category 1 Credit^TM.

Yes

Question Title

* 15. If you are claiming credit, please provide your contact information so we can send your certificate. Certificates will be provided within 4-6 weeks.

First Name *

Last Name *

Degree/Credentials:

City

State/Province

ZIP/Postal Code *

Country

Email Address (required to receive credit) *

Thank you for participating in our activity and completing the necessary paperwork. Your certificate will be emailed to you using the email address provided above. Please allow 4 weeks to receive your certificate.

For information about the certification of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Tweetorial #3: Best Practices with T-cell Therapy***Post-Survey & Application for CME Credit***

Question Title

* 1. What are your credentials?

Question Title

* 2. What is your community of practice?

Question Title

* 3. Based on an Association of Community Cancer Centers @ACCCBuzz survey conducted in 2020, which of the following challenges was most frequently cited as a barrier to treatment with bispecific antibodies?

Question Title

* 4. 74-YOM dx w/ IgG MM w/ t(11;14) here discuss tx with a bispecific ab. After explaining tx is continued until disease progression, he asks if he needs to receive tx and monitoring at an academic center. Which of the following is the best response regarding where tx is delivered?

Question Title

* 5. The director of the cancer center is exploring providing bispecific antibodies or CAR-T for multiple myeloma. Which of the following processes would need to be developed in order to provide both CAR-T and bispecific antibodies?

Question Title

* 6. Upon completion of this activity, I am able to:

Question Title

* 7. Please indicate the extent of your agreement with the following statements:

Question Title

* 8. Overall, was this activity fair, balanced and free from commercial bias?

Question Title

* 9. If no, please explain:

Question Title

* 10. Of the patients you will see in the next month, about how many will benefit from the information you learned today?

Question Title

* 11. As a result of what I learned, I intend to make changes in my practice:

Question Title

* 12. What change(s) will you incorporate into your practice as a result of what you have learned in this activity?

Question Title

* 13. Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):

Question Title

* 14. I certify that I have participated in the continuing education activity entitled, "Not Just Another Monoclonal Antibody: Best Practices for Providing T-cell Therapies" and claim 0.25 AMA PRA Category 1 CreditTM.

Question Title

* 15. If you are claiming credit, please provide your contact information so we can send your certificate. Certificates will be provided within 4-6 weeks.

Tweetorial #3: Best Practices with T-cell Therapy
Post-Survey & Application for CME Credit

* 14. I certify that I have participated in the continuing education activity entitled, "Not Just Another Monoclonal Antibody: Best Practices for Providing T-cell Therapies" and claim 0.25 AMA PRA Category 1 Credit^TM.